Biotech deals surge to record as fear of missing out grips Big Pharma

🇺🇸 Financial Times (US) —

AI Summary

Biotech mergers and acquisitions are surging to record levels as pharmaceutical companies seek to acquire innovations before key patents expire. This heightened deal activity highlights the industry's drive to find new blockbuster drugs.

Prospect of patents expiring on lucrative drugs prompts drugmakers to hunt for next blockbuster medicines

Markets Deals Health AI & Tech biotech pharmaceuticals mergers patents drug development blockbusters

Read original source →